BioSpace News Archive

Bay Area biotech firm renegade.bio today announced its partnership with Metabolomic Diagnostics, the Irish deep tech company specializing in the development of novel disease diagnostic solutions.

Carta Healthcare Inc., provider of solutions for common healthcare data challenges through a combination of people, processes, and artificial intelligence (AI)–powered technology, today announced that it has successfully completed a Type 1 System and Organization Controls 2 (SOC 2) examination for its Cartographer clinical data abstraction platform as of November 30, 2021.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”).

Lucy brings with her more than 10 years of industry experience focused on technology, process development and delivering large, complex projects.

Test Sites at Food City Locations in Phoenix and Mesa Deliver COVID-19 Test Results within 24 to 48 Hours.

Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR.

InspireMD, Inc. today announced the appointment of Adnan Siddiqui, MD, PhD, FAANS, FACS, FAHA to the Company’s Scientific Advisory Board.

Ipsen announced two-year follow-up results from analyses of the Phase III CheckMate -9ER trial, which demonstrated sustained survival and response rate benefits 1, as well as health-related quality of life improvements 2, with the combination of Cabometyx® and Opdivo® versus sunitinib in the first-line treatment of advanced renal cell carcinoma.

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company, announced its results for the financial year ended December 31, 2021, and strategic decisions to optimize the long-term value of its two business pillars, anti-infectives and oncology.

PureTech Health plc announced that Social Capital Suvretta Holdings Corp. I has filed with the U.S. Securities and Exchange Commission a registration statement on Form S-4, which contains a preliminary proxy statement/prospectus, in connection with the previously announced proposed business combination with Akili.